The University of Chicago Header Logo

Connection

Stuart Sprague to Aged

Back to Details
This is a "connection" page, showing publications Stuart Sprague has written about Aged.
Stuart Sprague
Connection Strength
0.770
Aged
  1. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
    View in: PubMed
    Score: 0.066
  2. Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease. Am J Nephrol. 2019; 49(2):114-124.
    View in: PubMed
    Score: 0.042
  3. Factors associated with health-related quality of life, hip function, and health utility after operative management of femoral neck fractures. Bone Joint J. 2018 03 01; 100-B(3):361-369.
    View in: PubMed
    Score: 0.040
  4. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67.
    View in: PubMed
    Score: 0.038
  5. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325.
    View in: PubMed
    Score: 0.036
  6. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12.
    View in: PubMed
    Score: 0.036
  7. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
    View in: PubMed
    Score: 0.033
  8. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45.
    View in: PubMed
    Score: 0.032
  9. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 05; 9(9):1620-6.
    View in: PubMed
    Score: 0.031
  10. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013 Feb; 61(2):310-25.
    View in: PubMed
    Score: 0.027
  11. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
    View in: PubMed
    Score: 0.022
  12. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
    View in: PubMed
    Score: 0.022
  13. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85.
    View in: PubMed
    Score: 0.021
  14. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
    View in: PubMed
    Score: 0.019
  15. Renal function and risk of hip and vertebral fractures in older women: is it always osteoporosis? Arch Intern Med. 2007 Jan 22; 167(2):115-6.
    View in: PubMed
    Score: 0.018
  16. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43.
    View in: PubMed
    Score: 0.018
  17. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006 Feb; 47(2):263-76.
    View in: PubMed
    Score: 0.017
  18. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005 Nov-Dec; 25(6):591-5.
    View in: PubMed
    Score: 0.017
  19. Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
    View in: PubMed
    Score: 0.016
  20. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 Jun; 41(6):2500-2518.
    View in: PubMed
    Score: 0.015
  21. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr; 63(4):1483-90.
    View in: PubMed
    Score: 0.014
  22. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol. 2002 Aug; 58(2):155-60.
    View in: PubMed
    Score: 0.013
  23. Medullary Blood Oxygen Level-Dependent MRI Index (R2*) is Associated with Annual Loss of Kidney Function in Moderate CKD. Am J Nephrol. 2020; 51(12):966-974.
    View in: PubMed
    Score: 0.012
  24. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
    View in: PubMed
    Score: 0.012
  25. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin J Am Soc Nephrol. 2020 06 08; 15(6):776-783.
    View in: PubMed
    Score: 0.012
  26. A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. J Am Soc Nephrol. 2020 01; 31(1):161-174.
    View in: PubMed
    Score: 0.011
  27. Renal BOLD MRI in patients with chronic kidney disease: comparison of the semi-automated twelve layer concentric objects (TLCO) and manual ROI methods. MAGMA. 2020 Feb; 33(1):113-120.
    View in: PubMed
    Score: 0.011
  28. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293.
    View in: PubMed
    Score: 0.011
  29. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999 Mar; 14(3):456-63.
    View in: PubMed
    Score: 0.011
  30. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. J Diabetes Complications. 2018 Dec; 32(12):1113-1117.
    View in: PubMed
    Score: 0.010
  31. Consistency of Multiple Renal Functional MRI Measurements Over 18 Months. J Magn Reson Imaging. 2018 08; 48(2):514-521.
    View in: PubMed
    Score: 0.010
  32. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1918-1926.
    View in: PubMed
    Score: 0.010
  33. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial Transplant. 1996; 11 Suppl 5:54-7.
    View in: PubMed
    Score: 0.009
  34. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40.
    View in: PubMed
    Score: 0.008
  35. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70.
    View in: PubMed
    Score: 0.008
  36. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep; 86(3):638-47.
    View in: PubMed
    Score: 0.008
  37. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7.
    View in: PubMed
    Score: 0.007
  38. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92.
    View in: PubMed
    Score: 0.006
  39. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45.
    View in: PubMed
    Score: 0.005
  40. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93.
    View in: PubMed
    Score: 0.004
  41. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90.
    View in: PubMed
    Score: 0.004
  42. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
    View in: PubMed
    Score: 0.003
  43. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl. 2002 Oct; (81):S23-33.
    View in: PubMed
    Score: 0.003
  44. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg. 1989 Dec; 98(6):1107-12.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.